Connection
Ahmad Dbouk to Cost-Benefit Analysis
This is a "connection" page, showing publications Ahmad Dbouk has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.030 |
|
|
|
-
Shaker M, Briggs A, Dbouk A, Dutille E, Oppenheimer J, Greenhawt M. Estimation of Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and Mepolizumab. J Allergy Clin Immunol Pract. 2020 02; 8(2):565-572.
Score: 0.030